Clin2
NCT07540910Likely a fitRecruiting

Safety study of EDP-978 in healthy adults

Chronic Inducible UrticariaChronic Spontaneous Urticaria

Part of Immune system & allergy, Skin clinical trials.

This is an early-stage study testing a new experimental drug called EDP-978 in healthy volunteers to see if it is safe and how the body processes it. Researchers will give participants single or multiple doses and monitor for side effects and how the drug moves through the body.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
98 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be between 18 and 65 years old and in generally good health
  • You cannot be pregnant, nursing, or planning to become pregnant during the study
  • You must not have HIV, hepatitis B, hepatitis C, or active COVID-19
  • You cannot smoke or have used tobacco in the past 3 months
  • You must not use recreational drugs or have a history of heavy alcohol use
  • You cannot have had recent surgery on your stomach, intestines, or gallbladder that might affect how your body absorbs medicine

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07686484Recruiting· Early Phase 1
Testing a new drug in healthy volunteers

This trial tests an experimental drug called HRS-3095 in healthy people to check its safety and how the body handles it. It may help find the right dose for future studies.

Bayswater, Victoria
NCT06864507Not yet recruiting· Phase 1/Phase 2
Study of HS-10561 for healthy adults and chronic hives patients

This trial tests a new medication (HS-10561) first in healthy adults to check safety, then in people with chronic spontaneous urticaria (long-term hives without a known cause) to see if it helps reduce symptoms. It may be an option for those who have had hives for at least 6 months.

Shanghai, Shanghai Municipality
NCT07717905Recruiting· Phase 1/Phase 2
Testing BBT001 for chronic hives

This trial tests a new medicine called BBT001 for people with chronic spontaneous urticaria (long-lasting hives without a known cause). It aims to see if the drug is safe and helps reduce itching and hives.

Wuhu, Anhui
NCT07181369Recruiting· Phase 1
Study of GTX-B001 for chronic inducible urticaria

This trial tests a new drug, GTX-B001, in healthy people and those with a type of hives called chronic inducible urticaria (specifically cold-induced or scratch-induced hives). The goal is to see if it's safe and helps control symptoms that don't respond well to standard antihistamines.

Berlin
NCT07402213Recruiting· Phase 3
Study of JYB1904 for chronic spontaneous urticaria

This trial tests a new injectable medicine (JYB1904) to see if it can reduce itching and hives better than standard antihistamines alone. If you have chronic hives with no clear cause and still get symptoms despite taking antihistamines, this study may be an option for you.

Beijing
NCT07613866Not yet recruiting· Phase 2
HRS-3095 for Hard-to-Treat Chronic Hives

This trial tests a new medication (HRS-3095) for chronic spontaneous urticaria—persistent hives that don't go away despite taking standard antihistamine pills. If your hives have lasted months and remain poorly controlled, this study may help you find relief.

Shanghai, Shanghai Municipality

Hear when a new Chronic Inducible Urticaria trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.